Citrate | No anticoagulation | P | |
---|---|---|---|
Primary endpoint | |||
Completed sessions | 14/14 | 9/13 | 0.04 |
Secondary endpoints | |||
Clotting score dialyzer (n) | 0.009 | ||
Clean, white | 2 | 2 | |
White, limited fibrin deposits, head of dialyzer | 7 | 3 | |
White, fibrin deposits head and body dialyzer | 5 | 5 | |
Completely clotted, rinse back successful | 0 | 1 | |
Completely clotted, rinse back unsuccessful | 0 | 2 | |
Platelets (x 103/mm3) | |||
Start of treatment | 112 (58 - 146) | 92 (67 - 169) | 0.6 |
End of treatment | 85 (67 - 162) | 89 (60 - 117) | 0.7 |
Reduction of platelets (P intra-group) | 12 (P 0.08) | 28 (P 0.0005) | 0.03 |
aPTT (s) | |||
Start of treatment | 44.1 (40.5 - 57.2) | 57.8 (40.7 - 75.4) | 0.5 |
End of treatment | 48.0 (41.3 - 61.5) | 52.5 (40.0 - 65.7) | 0.6 |
PT (s) | |||
Start of treatment | 14.2 (13.8 - 16.0) | 17.2 (14.6 - 22.0) | 0.1 |
End of treatment | 14.5 (14.0 - 16.2) | 16.1 (13.8 - 18.3) | 0.4 |
TAT complex (μg/L) | |||
End of treatment | 9.9 (7.7 - 91.7) | 25.7 (19.5 - 40.5) | 0.3 |
Increase during treatment | 6.1 (5.1 - 50.1) | 25.1 (16.8 - 40.5) | 0.09 |
Treatment efficacy, all sessions | |||
Urea reduction ratio | 0.51 (0.14) | 0.40 (0.14) | 0.06 |
Creatinine reduction ratio | 0.40 (0.13) | 0.31 (0.17) | 0.10 |
Bilirubin (total) reduction ratio | 0.25 (0.09) | 0.15 (0.10) | 0.02 |
Bile acids reduction ratio | 0.47 (0.20) | 0.42 (0.16) | 0.34 |
Treatment efficacy, completed sessions | |||
Urea reduction ratio | 0.51 (0.14) | 0.46 (0.12) | 0.4 |
Creatinine reduction ratio | 0.40 (0.13) | 0.40 (0.14) | 0.9 |
Bilirubin (total) reduction ratio | 0.25 (0.09) | 0.18 (0.09) | 0.1 |
Bile acids reduction ratio | 0.47 (0.20) | 0.46 (0.21) | 0.9 |